Condition: Juvenile Idiopathic Arthritis (JIA) · Sponsor: Assistance Publique - Hôpitaux de Paris
The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.
This description comes directly from the study's public registry record.
Yannick ALLANORE, PD, PhD · 0033158412563 · yannick.allanore@aphp.fr
Marie BENHAMMANI-GODARD · +33 1 58411190 · marie.godard@aphp.fr
Always discuss trial participation with your own doctor first.
| Rheumatology Department, Cochin Hospital | Paris, IDF, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05534347